《海洋药物》：岩藻多糖作为结肠癌辅助治疗的临床研究
2020-06-19
原标题：岩藻多糖作为转移结肠癌患者辅助治疗：双盲随机临床试验
①岩藻多糖被广泛用于癌症患者饮食治疗，但目前的研究大都是针对体外或小鼠实验，有效的临床证据相对缺乏；
②本研究评价了岩藻多糖作为转移结肠癌患者的辅助治疗效果，采用双盲随机临床试验，一共54名结肠癌患者，28名试验组，26名对照组，主要评价指标包括疾病控制率、生存期、总体存活率、副反应及生活质量；
③试验结果：岩藻多糖组的疾病控制率高达92.8%，对照组69.2%；岩藻多糖组总生存期为18.04±0.91个月，显著高于对照组的12.96±0.83个月；；
④此外，研究发现岩藻多糖组的副作用得到显著缓解，例如：岩藻多糖组的口腔黏膜炎发病率50%（对照组65.4%）、皮肤瘙痒发生率35.7%（对照组53.9%）、呕吐发生率35.7%（对照组53.9%）、味觉障碍发生率64.3%（对照组80.8%）、血便发生率14.3%（对照组30.8%）。
⑤结论：岩藻多糖可以作为转移结肠癌患者辅助治疗，可以帮助患者缓解副作用，控制疾病发展。
延伸阅读
Mar. Drugs 2017, 15, 122-133.
Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial
Abstract:
Background: Low-molecular-weight fucoidan (LMF) is widely used as a food supplement for cancer patients. However, all of the studies are in vitro or were conducted using mice. Therefore, powerful clinical evidence for LMF use is relatively weak. This study aimed to evaluate the efficacy of LMF as a supplemental therapy to chemo-target agents in metastatic colorectal cancer (mCRC) patients. Methods: We conducted a prospective, randomized, double-blind, controlled trial to evaluate the efficacy of LMF as a supplemental therapy to chemotarget agents in patients with metastatic colorectal cancer (mCRC). Sixty eligible patients with mCRC were included. Finally, 54 patients were enrolled, of whom 28 were included in the study group and 26 in the control group. The primary endpoint was the disease control rate (DCR), and secondary endpoints included the overall response rate (ORR), progression-free survival (PFS), overall survival (OS), adverse effects (AEs), and quality of life (QOL). Results: The DCRs were 92.8% and 69.2% in the study and control groups, respectively (p = 0.026), in a median follow-up period of 11.5 months. The OS, PFS, ORR, AEs, and QOL did not significantly differ between the two groups. Conclusion: This is the first clinical trial evaluating the efficacy of LMF as a supplemental therapy in the management of patients with mCRC. The results indicate that LMF combined with chemotarget agents significantly improved the DCR.
First Authors:
Hsiang-Lin Tsai
Correspondence:
Jaw-Yuan Wang
All Authors:
Hsiang-Lin Tsai, Chi-Jung Tai, Ching-Wen Huang, Fang-Rong Chang and Jaw-Yuan Wang
2017-04-21 Article
